Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ID: DRG0HQVXQ)
| ADC Name |
Zarutatug vedotin
|
|||||
|---|---|---|---|---|---|---|
| Synonyms |
zarutatug vedotin; TORL-3-600
Click to Show/Hide
|
|||||
| Organization |
TORL Biotherapeutics (Originator)
|
|||||
| Drug Status |
Phase 1 (discontinued)
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Zarutatug
|
Antibody Info | ||||
| Antigen Name |
Cadherin-17 (CDH17)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Payload Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
2027 Update
The disease landscape of This ADC
2027 Update
The clinical trial pipelines of This ADC
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Eligible patients must have advanced solid tumors with measurable disease (RECIST v1.1), ECOG 0-1, and adequate organ function. Exclusions include unresolved toxicities (>Grade 1, except alopecia), recent anticancer therapy (14-28 days prior), active brain metastases, uncontrolled comorbidities, cardiac disease, MDS/AML history, concurrent malignancies (except certain low-risk cases), and pregnancy/breastfeeding.
Click to Show/Hide
|
||||
| Administration Dosage |
.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT05948826 | Clinical Status | PHASE1 | ||
| Clinical Description | A Phase 1, First in Human, Dose-Escalation Study of TORL-3-600 in Participants With Advanced Cancer | ||||
| Primary Endpoint |
The study will assess the incidence and severity of adverse events (AEs) and serious adverse events (SAEs) graded by NCI-CTCAE v5.0 over 2 years, while determining Maximum Tolerated Dose (MTD) based on dose-limiting toxicities (DLTs) in the first 6 evaluable participants within 28 days, and Recommended Phase 2 Dose (RP2D) using safety, tolerability, and pharmacokinetic data.
Click to Show/Hide
|
||||
| Other Endpoint |
Efficacy endpoints include Objective Response Rate (ORR), Duration of Response (DOR), Progression-Free Survival (PFS), Time to Response (TTR), 1-Year and 2-Year Overall Survival (1YOS, 2YOS), and immunogenicity via anti-drug antibody (ADA) assessment. Pharmacokinetic parameters [Cmax, Cmin, AUC, t1/2, CL, Vz, Rac, etc.] for TORL-3-600 will be evaluated over 21-63 days.
Click to Show/Hide
|
||||